Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous low-dose rituximab versus intravenous rituximab in rheumatoid arthritis
NL-OMON20186Not yet recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Sint Maartenskliniek. Primary endpoint: Pharmacokinetic non-inferiority based on AUC over 0 to 6 months. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON20186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20186.